Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Assets (2019 - 2026)

Biodesix filings provide 8 years of Assets readings, the most recent being $94.6 million for Q1 2026.

  • On a quarterly basis, Assets rose 9.74% to $94.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $94.6 million, a 9.74% increase, with the full-year FY2025 number at $87.5 million, down 10.04% from a year prior.
  • Assets hit $94.6 million in Q1 2026 for Biodesix, up from $87.5 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $115.8 million in Q2 2024 to a low of $61.7 million in Q1 2022.
  • Median Assets over the past 5 years was $87.5 million (2025), compared with a mean of $87.4 million.
  • Biggest five-year swings in Assets: tumbled 46.62% in 2022 and later skyrocketed 49.24% in 2024.
  • Biodesix's Assets stood at $92.9 million in 2022, then increased by 6.66% to $99.1 million in 2023, then decreased by 1.87% to $97.2 million in 2024, then fell by 10.04% to $87.5 million in 2025, then increased by 8.19% to $94.6 million in 2026.
  • The last three reported values for Assets were $94.6 million (Q1 2026), $87.5 million (Q4 2025), and $88.7 million (Q3 2025) per Business Quant data.